2022
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L, Ezzat S, de Herder W, Klimstra D, Papotti M, Asa S. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 2022, 33: 115-154. PMID: 35294740, DOI: 10.1007/s12022-022-09708-2.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsNeuroendocrine neoplasmsSomatostatin receptorsWHO classificationNon-neuroendocrineDifferential diagnosisWHO Classification of EndocrineExpression of somatostatin receptorsWHO classification of neuroendocrine neoplasmsG3 neuroendocrine tumorsAssociated with germline mutationsPancreatic neuroendocrine tumorsClassification of neuroendocrine neoplasmsEctopic hormone productionLoss of RbLoss of ATRXSite of originComposite tumorMetastatic lesionsAberrant p53Amphicrine tumorsEpithelial neoplasmsPrecursor lesionsTheranostic biomarkersGermline mutations
2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database
Punekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.Peer-Reviewed Original ResearchConceptsG3 neuroendocrine tumorsColorectal neuroendocrine tumorsNeuroendocrine tumorsOverall survivalUnmarried patientsCox proportional hazards modelEnd Results (SEER) databaseGastrointestinal neuroendocrine tumorsPredictors of survivalPrognosis of patientsNational registry studyProportional hazards modelOlder patientsRegistry studySEER databaseWorse survivalMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsHazards modelPatientsSmall studyLogistic regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply